Amgen stock holds near a yearly high after Q2 beats
Published on 08/13/2026 at 11:08 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Amgen stock is holding near a yearly high after the company reported second-quarter 2026 revenue of $10.05 billion and adjusted EPS of $6.29, while the shares were quoted around $414.30 on August 11, 2026. The latest market snapshot also put Amgen's market value near $223.98 billion, giving investors a fresh read on how strongly the Q2 numbers were received.
Q2 strength and higher guidance
In the second quarter, revenue rose 9.5 percent year over year to $10.05 billion and adjusted EPS came in 12 percent above analyst expectations, according to a summary of the earnings call. The company also lifted full-year 2026 revenue guidance to $38.2 billion-$39.4 billion and raised non-GAAP EPS guidance to $22.30-$23.50.
That combination matters because the quarter was not just a beat, it also came with a wider full-year range. MarketBeat's stock snapshot showed Amgen opening at $414.30 on August 12, 2026, close to its 52-week high of $421.79, while the 52-week low stood at $269.77.
What the market is pricing
The stock's 43.19 percent one-year gain in the Investing.com history table suggests that the market has already been rewarding execution before the latest update. TradingKey's market page also showed a market cap of $224.80 billion and a closing price of $415.84 on August 12, 2026, underscoring how firmly the shares are trading above their long-term floor.
For investors, the comparison to watch is simple: revenue grew 9.5 percent in Q2 2026 while guidance for the full year moved up, so the debate shifts from whether Amgen can beat to how long the current pace can last.
Pipeline breadth
Amgen's product mix still matters because management said six growth drivers now account for nearly 70 percent of total product sales, with products such as Repatha, EVENITY and TEZSPIRE helping the quarter. The company also flagged nine ongoing Phase 3 trials for MariTide and projected about $2.6 billion in capital expenditures for 2026 to expand manufacturing capacity.
Amgen shares today
Amgen shares closed at $415.84 on August 12, 2026, after a 0.37 percent move, with TradingKey's page showing the stock near a market cap of $224.80 billion. The shares remain within reach of the $421.79 52-week high.
Amgen at a glance
- Company: Amgen Inc.
- ISIN: US0311621009
- Ticker: AMGN
- Exchange: Nasdaq
- Price (as of August 12, 2026, 4:00 p.m. ET): $415.84 USD
- Market cap: $224.80 billion (as of August 12, 2026)
- Sector / Industry: Healthcare / Biotechnology
- Index membership: S&P 500
- Next earnings date: not yet officially scheduled
